{
    "clinical_study": {
        "@rank": "131175", 
        "arm_group": [
            {
                "arm_group_label": "A- 4mg QD", 
                "arm_group_type": "Experimental", 
                "description": "arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent"
            }, 
            {
                "arm_group_label": "B- 5mg once daily, 3wks on/1wk off", 
                "arm_group_type": "Experimental", 
                "description": "arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent"
            }
        ], 
        "brief_summary": {
            "textblock": "Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison\n      MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1,\n      2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor\n      xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and\n      efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these\n      2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and\n      regimen in phase II/III study."
        }, 
        "brief_title": "Phase Ib Study of Fruquintinib in Patients With Metastatic Colorectal Carcinoma", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Colorectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase Ib, randomize, interventional, open-label,  multicenter study to provide\n      fruquintinib to subjects diagnosed with metastatic colorectal cancer who have failed after\n      standard therapy and for whom no therapy alternatives exist.\n\n      The primary endpoint of this study will be safety."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 and \u2264 70 years of age , with \u2265 40Kg\n\n          -  Histological or cytological confirmed colorectal cancer\n\n          -  ECOG performance status of 0-1\n\n          -  Standard regimen failed or no standard regimen available\n\n          -  Adequate hepatic, renal, heart, and hematologic functions\n\n          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)\n\n          -  Signed and dated informed consent.\n\n          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory\n             tests, and other study procedure\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Any factors that influence the usage of oral administration\n\n          -  Evidence of CNS metastasis\n\n          -  Intercurrence with one of the following: non-controlled hypertension, coronary artery\n             disease, arrhythmia and heart failure\n\n          -  Abuse of alcohol or drugs\n\n          -  Less than 4 weeks from the last clinical trial\n\n          -  Previous treatment with VEGFR inhibition\n\n          -  Disability of serious uncontrolled intercurrence infection\n\n          -  Proteinuria \u2265 2+ (1.0g/24hr)\n\n          -  Uncontrolled hemorrhage in GI\n\n          -  Within 12 months before the first treatment occurs artery/venous thromboembolic\n             events, such as cerebral vascular accident (including transient ischemic attack) etc.\n\n          -  Within 6 months before the first treatment occurs acute myocardial infarction, acute\n             coronary syndrome or CABG\n\n          -  Bone fracture or wounds that was not cured for a long time\n\n          -  Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975077", 
            "org_study_id": "2012-013-00CH3"
        }, 
        "intervention": {
            "arm_group_label": [
                "A- 4mg QD", 
                "B- 5mg once daily, 3wks on/1wk off"
            ], 
            "description": "Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily", 
            "intervention_name": "fruquintinib", 
            "intervention_type": "Drug", 
            "other_name": "HMPL-013"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "patients with mCRC who failed 2nd therapy or more", 
        "lastchanged_date": "October 28, 2013", 
        "location": [
            {
                "contact": {
                    "email": "huam@hmplglobal.com", 
                    "last_name": "Hua Mu, PhD, MD", 
                    "phone": "8621-50790088", 
                    "phone_ext": "321"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510060"
                    }, 
                    "name": "Sun Yat-sen University Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ruihua Xu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "huam@hmplglobal.com", 
                    "last_name": "Hua Mu, PhD, MD", 
                    "phone": "8621-50790088", 
                    "phone_ext": "321"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200032"
                    }, 
                    "name": "Fudan University Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jin Li, PhD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label Phase Ib Trial of Fruquintinib \"4mg Once Daily Continuous\"Versus \"5mg Once Daily 3wks on/1wk Off\" in Patients With Metastatic Colorectal Carcinoma as 3rd Therapy", 
        "overall_contact": {
            "email": "huam@hmplglobal.com", 
            "last_name": "Hua Mu, PhD. MD", 
            "phone": "8621-50790088", 
            "phone_ext": "321"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is evaluation of safety and tolerabilty with 2 regimens. The primary endpoint is the incidence of AEs, SAEs, Gr3/4 AEs and AEs led to dose interruption and dose discontinued", 
            "measure": "safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "from day 1 of  first dosing to 30days after permanent discontinuation of HMPL-013"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975077"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "objective response rate(ORR)", 
                "measure": "efficacy (tumor assessment every 8 weeks till end of treatment)", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months"
            }, 
            {
                "description": "disease control rate (DCR)", 
                "measure": "efficacy", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months"
            }, 
            {
                "description": "Progression-free suvival (PFS)", 
                "measure": "efficacy", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months"
            }, 
            {
                "description": "overall survival (OS)", 
                "measure": "efficacy", 
                "safety_issue": "No", 
                "time_frame": "every 3 months until  date of death from any cause,  assessed up to 20 months"
            }, 
            {
                "description": "At QD regimen, PK sampling will include a pre-dose and at the 1,2,4,8,24 hour time points on day 1 and day 21;a pre-dose and at the 2 hour time point on day 28,42,70,84.\nAt 3wks on/1wk off regimen,PK sampling will  include a pre-dose and  at the 1,2,4,8,24 hour time points on day 1 and day 21; a pre-dose and at the 2 hour time point on day 42 and day 70; only pre-dose on day 28,56,84.", 
                "measure": "pharmacokinetic profiles", 
                "safety_issue": "No", 
                "time_frame": "Day 1-84 steady state"
            }
        ], 
        "source": "Hutchison Medipharma Limited", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Fudan University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sun Yat-sen University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hutchison Medipharma Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}